Oculis Elects Gregory D. Perry, Authorizes CHF80.25 Million Loss Carryforward and Equity Awards
Oculis’ 2026 AGM carried forward a CHF80.25 million loss, acknowledged a 2025 loss of CHF33.67 million and authorized a 31 million-share capital band. The board named Gregory D. Perry and approved USD2.15 million in director equity and USD18 million in executive equity awards.
1. AGM Financial Resolutions
At the Annual General Meeting on May 13, shareholders approved the standalone 2025 statutory loss of CHF33.67 million and resolved to carry forward an accumulated balance sheet loss of CHF80.25 million. Delegates also authorized a capital band permitting issuance of up to 31,020,888 registered shares.
2. Board Composition Changes
All existing directors were re-elected, with Anthony Rosenberg continuing as chair. Gregory D. Perry, former CFO of Merus N.V. and Finch Therapeutics, was newly appointed, bringing extensive transatlantic biotech finance and governance experience.
3. Compensation Packages Approved
Shareholders ratified maximum fixed non-executive director compensation of USD572,000 and equity awards up to USD2,150,000 through the 2027 AGM. For the Executive Committee, they approved up to USD2,500,000 fixed, USD1,800,000 variable and USD18,000,000 in equity-based compensation.
4. Share Issuance and Capital Band Details
Following updates to the Articles of Association, Oculis’ registered share count rose to 62,041,776, including 2,872,301 shares from equity plan exercises. The board also approved issuance of 5,750,400 treasury shares under the newly authorized capital band.